These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 38339243)

  • 1. The Role of the Complement in Clear Cell Renal Carcinoma (ccRCC)-What Future Prospects Are There for Its Use in Clinical Practice?
    Panebianco M; Ciccarese C; Strusi A; Beccia V; Carbone C; Agostini A; Piro G; Tortora G; Iacovelli R
    Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer.
    Raimondi A; Sepe P; Zattarin E; Mennitto A; Stellato M; Claps M; Guadalupi V; Verzoni E; de Braud F; Procopio G
    Front Oncol; 2020; 10():1644. PubMed ID: 32903369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review.
    Rebuzzi SE; Perrone F; Bersanelli M; Bregni G; Milella M; Buti S
    Expert Rev Mol Diagn; 2020 Feb; 20(2):169-185. PubMed ID: 31608727
    [No Abstract]   [Full Text] [Related]  

  • 5. Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort.
    Barata P; Hatton W; Desai A; Koshkin V; Jaeger E; Manogue C; Cotogno P; Light M; Lewis B; Layton J; Sartor O; Basu A; Kilari D; Emamekhoo H; Bilen MA
    Front Oncol; 2020; 10():581189. PubMed ID: 33194712
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials.
    Rizzo A; Mollica V; Santoni M; Ricci AD; Rosellini M; Marchetti A; Montironi R; Ardizzoni A; Massari F
    Eur Urol Focus; 2022 Mar; 8(2):514-521. PubMed ID: 33714725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
    Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
    Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological Biomarkers of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma.
    Masson C; Thouvenin J; Boudier P; Maillet D; Kuchler-Bopp S; Barthélémy P; Massfelder T
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations.
    Iacovelli R; Ciccarese C; Procopio G; Astore S; Cannella MA; Maratta MG; Rizzo M; Verzoni E; Porta C; Tortora G
    Cancer Treat Rev; 2022 Apr; 105():102379. PubMed ID: 35303548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
    de Velasco G; Culhane AC; Fay AP; Hakimi AA; Voss MH; Tannir NM; Tamboli P; Appleman LJ; Bellmunt J; Kimryn Rathmell W; Albiges L; Hsieh JJ; Heng DY; Signoretti S; Choueiri TK
    Oncologist; 2017 Mar; 22(3):286-292. PubMed ID: 28220024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergies of Antiangiogenic Therapy and Immune Checkpoint Blockade in Renal Cell Carcinoma: From Theoretical Background to Clinical Reality.
    Zhou X; Hou W; Gao L; Shui L; Yi C; Zhu H
    Front Oncol; 2020; 10():1321. PubMed ID: 32850419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
    de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
    Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
    Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Mori K; Abufaraj M; Mostafaei H; Quhal F; Fajkovic H; Remzi M; Karakiewicz PI; Egawa S; Schmidinger M; Shariat SF; Gust KM
    Eur Urol; 2021 Jun; 79(6):783-792. PubMed ID: 33172722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging resistance
    Roy AM; George S
    Cancer Drug Resist; 2023; 6(3):642-655. PubMed ID: 37842239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status.
    Carril-Ajuria L; Colomba E; Romero-Ferreiro C; Cerbone L; Ratta R; Barthelemy P; Vindry C; Fléchon A; Cherifi F; Boughalem E; Linassier C; Fornarini G; Rebuzzi SE; Gross-Goupil M; Saldana C; Martin-Soberón M; de Velasco G; Manneh R; Pernaut C; Sanchez de Torre A; Flippot R; Escudier B; Albiges L
    Eur J Cancer; 2023 Feb; 180():21-29. PubMed ID: 36527973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma.
    Jo H; Hong J; Kim H; Kim HR; Kwon GY; Kang KA; Park SY; Kim CK; Park BK; Chung JH; Song W; Kang M; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Park SH
    Front Oncol; 2022; 12():874385. PubMed ID: 35574412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of gut microbiome in immune modulation in metastatic renal cell carcinoma.
    Deluce J; Maleki Vareki S; Fernandes R
    Ther Adv Med Oncol; 2022; 14():17588359221122714. PubMed ID: 36105887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Circulating Tumor DNA in Renal Cell Carcinoma.
    Bergerot PG; Hahn AW; Bergerot CD; Jones J; Pal SK
    Curr Treat Options Oncol; 2018 Feb; 19(2):10. PubMed ID: 29464405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma.
    Rassy E; Flippot R; Albiges L
    Ther Adv Med Oncol; 2020; 12():1758835920907504. PubMed ID: 32215057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.